A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Sionna Therapeutics hopes to raise $150 million and secure a market capitalization of about $692 million in an initial public ...
Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and ...
11d
Sophie would make a world record for being the first man or woman with cystic fibrosis to row across the Atlantic, while at ...
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...
GlobalData on MSN4d
FDA approves Vertex’s acute pain treatment JournavxThe FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
By the time Enid Katz was two years old, she had already suffered through several bouts of bronchitis and was always hungry, ...
Glox Therapeutics secures £500K from a £3M fund to develop antibiotics targeting antimicrobial-resistant lung infections in ...
Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback